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Introduction
Aldehyde oxidase (AO) and xanthine oxidase (XO) are closely related molybdoflavo proteins in cytosolic fractions and show a high degree of homology in their amino acid sequence (Beedham, 1985) . However, the substrate specificities of AO and XO do differ. Physiological function of XO has long been recognized in the catabolism of purines, starting with the oxidation of hypoxanthine to xanthine, and then to uric acid (Kitamura et al., 2006) . On the other hand, the biochemical and physiological role of AO is still nebulous (Kitamura et al., 2006; Garattini and Terao, 2011) . AO catalyzes the oxidation of a number of aldehydes, and nitrogen containing heterocyclic xenobiotics and drug molecules such as methotrexate, cyclophosphamide, acyclovir, famciclovir, and zaleplon (Kitamura et al., 2006; Pryde et al., 2010) . However, in the presence of an electron donor, both AO and XO can catalyze reduction as well, using a variety of substrates like sulfoxides, N-oxides, nitrosamines, hydroxamic acids, azodyes, and oximes derivatives (Tatsumi et al., 1983; Sugihara et al., 1997; Kitamura et al., 2006; Pryde et al., 2010) , albeit oxidation reactions are far more common. In general, AO has the ability to oxidize a broader range of substrates than XO.
Oxidations by AO generally involve nucleophilic catalysis and often occur in electrondeficient ring systems, resulting in metabolites different from those via electrophilic oxidations by cytochrome P450 system. A number of reviews have been written on the subject of oxidation by AO (Kitamura et al., 2006; Pryde et al., 2010) . More recently, Pryde et. al.(Pryde et al., 2010) reviewed common aromatic heterocyclic compounds containing structural motifs which are known to be oxidized by AO. Notable structures included electron-deficient 6 DMD #44545 membered-heterocycles such as pyridines, pyrimidines, pyrazines, and their fused ring analogues.
Five membered azoles are frequently used in medicinal chemistry as common pharmacophores and also as bioisosteres for esters and amides to prevent hydrolytic instability and improve metabolic stability and other drug-like properties (Dalvie et al., 2002; Chen and Wang, 2003; Dua et al., 2011) . Compared to π-rich pyrroles, furans and thiophenes, azole and isoazole ring systems contain an additional nitrogen atom as a new site of basicity and have reduced π-electron density due to decrease in the energy levels of the π-orbitals. Both of these properties lead to lower susceptibility to oxidative metabolism catalyzed by cytochrome P-450. Despite AO and XO are known to catalyze reductive N-O bond cleavage of isoxazoles and isothiazoles (Kitamura et al., 2006; Pryde et al., 2010) , typical azoles such as oxazoles have not been reported as a substrate for AO or XO.
However, during our recent biotransformation studies of drug discovery compounds, we observed a novel ring oxidation on the oxazole substructure catalyzed by AO. The oxidation occurs on various 4-or 5-substituted but C2-unsubstituted oxazoles (2H-oxazoles) and forms corresponding 2-oxazolone, a cyclic carbamate (Fig.   7 ), as products. In this article, we demonstrate evidence of the AO-mediated oxidation using a model compound, 5-(3-bromophenyl)oxazole (5BPO), along with a number of related oxazoles.
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Liver cytosol incubations and half life determinations. Incubations in liver cytosols were performed in duplicate using Tecan liquid handler in a 96 well plate as above. First a mixture of 490 µL of liver cytosol (diluted to concentration of 0.5 mg/mL in potassium phosphate buffer, 100 mM, pH 7.4) and 5 µL of 50% aq. DMSO was pre incubated at 37 °C for 3 mins. Following which an appropriate compound/substrate (5 µL x 0.5 mM in 50% aq. DMSO) was added to the incubation mixture and subsequently, the mixture was allowed to incubate for additional 0.5 hr. The final concentration of substrate was 5 µM and the total incubation volume was 0.5 mL. Aliquots of samples were taken at 0 (immediately following addition of substrate), 15 and 30 min. Reactions were quenched by adding equal volumes of acetonitrile and were processed as in liver microsomes.
Half life of 5BPO and other 4-or 5-substituted or ring-fused 2H oxazole compounds in liver cytosols was determined using the procedures discussed above, except that incubations were carried out up to 240 min. An aliquot of samples were taken at 0,1, 3, 5, 10, 30, 60, 90, 120, 180 , and 240 mins. Percentage of parent remaining was calculated based on LC-UV (λmax) peak area of parent oxazoles at various times.
In a separate experiment effect of various molybdenum hydroxylase inhibitors on formation of M1 was studied by carrying out incubations in a similar fashion as above.
Initially, a mixture of 490 µL of diluted liver cytosol (0.5 mg/mL) and 5 µL of chemical inhibitor in 50% aq. DMSO was pre-incubated at 37°C for 3 min followed by addition of substrate (5 µL, 0.5 mM in 50% aq. DMSO). The chemical inhibitors were added at final incubation concentrations of 100 µM, except for raloxifene, which was used at a final LC separation was performed using the following gradient conditions: initially solvents were held isocratically at 0% solvent B for 0.5 min, followed by a linear gradient to 100% solvent B over 23 min. Solvent B was then held isocratic at 100% for 3 min, followed by immediate return to 0% solvent B in 0.1 min, and re-equilibrated for 4.9 min. Total LC DMD #44545 separation run time was 31.5 min. The eluent from the HPLC column was routed in-line to an Agilent1100 series photodiode-array detector (scanning 200-600 nm at 5 Hz) and then to a ThermoFinnigan LTQ orbitrap ion trap mass spectrometer (San Jose, CA). All samples were analyzed using electro-spray source in positive ion mode. The product ion mass spectra were acquired using CID energy of 45 % in data-dependent production scanning mode.
Purification of metabolite M1 of 5-(3-bromophenyl)oxazole. 5-(3-bromophenyl)oxazole (5BPO, 10 µM) was incubated in 30 mL (6 x 5mL) of mouse liver cytosol at higher protein concentrations, 1 mg/mL for 60 min. Under the scale-up incubation conditions, the LC-UV profile showed that 5BPO was completely consumed and converted to M1. Reaction was terminated by the addition of equal volume of acetonitrile as above. After centrifugation at 16000 x g for 2 min., resulting supernatant was dried under stream of dry nitrogen and reconstituted in 800 µL of 50/50 mixture of methanol:water, mixed, and centrifuged. Resulting supernatant was injected onto HPLC system by multiple injections for isolation and purification of M1 using a published methodology (Johnson et al., 2010) . Fractions (0.4 min/well) were collected in a 96 well plate. The fractions containing M1 as determined by LC-UV were combined and evaporated to dryness under nitrogen.
NMR analysis of M1 of 5-(3-bromophenyl)oxazole. The isolated M1 was analyzed using a Bruker AV500 NMR spectrometer. The sample was dissolved in 150 Interestingly, the microsomal incubation of 5BPO without addition of NADPH only yielded M1 (6%) but not M2 (Fig. 1, panel A) , suggesting that while M2 appeared to be a cytochrome P450 mediated metabolite, the formation of M1 was likely due to the catalysis by residual cytosolic components present in the mouse liver microsomes. Collectively, these ions suggested that the additional oxygen atom was likely introduced to the oxazole at C2 position in M1. It is known that C2-hydroxyl on oxazole exists in its thermodynamically stable 2-oxazolone form rather than the 2-hydroxyl tautomeric 
Results
Biotransformation
Confirmation of M1 structure by NMR.
In order to confirm the proposed structure of M1 ( Fig. 4B) , it was isolated and purified from a larger incubation of 5BPO
(10 µM, 6 x 5mL) in mouse liver cytosol using a higher protein concentration (1 mg/mL).
The purified M1 was then subjected to 1D and 2D NMR analysis. Proton NMR spectrum of M1 was very diagnostic and the modification on the oxazole ring was indicated by the absence of the singlet proton, at either position C2-H at δ8.28 or C4-H at δ7.58 present in the 1H NMR spectrum of 5BPO (Fig. 6) . All proton resonances and coupling pattern belonging to the bromophenyl group in M1 observed were same as in 5BPO ( 5BPO Incubation in liver cytosol from different animal species. 5BPO (5 µM) was incubated in liver cytosols (0.5 mg/mL) from various animal species including the rat, mouse, dog, monkey, and human and samples were analyzed by LC-UV/MS/MS at multiple time points up to 240 min. Table 3 shows T1/2 obtained from measuring 5BPO disappearance in cytosols across species. Maximum turnover of 5BPO was observed in mouse liver cytosol (T1/2 = 7 min) followed by monkey liver cytosol (217 min). M1 was the only metabolite detected in these incubations. Relative percentage of M1, based on LC-UV area was 89% in mouse and 10% in monkey liver cytosol at 30 min of incubation. Whereas only trace amount of M1 was detected in rat and human liver cytosols. Dog liver cytosol, however, did not show any formation of M1.
Biotransformation of other 4-or 5-substituted or ring-fused 2H oxazoles in mouse liver cytosol. The compounds investigated were C5-substituted oxazole, 5-(3-chlorophenyl)oxazole and merimepodib, and C4-substituted oxazole: 4-(2-bromophenyl)oxazole, and 4, 5-di-substituted 2H-oxazoles (Table 4) . These compounds were incubated in mouse liver cytosol at a substrate concentration of 5 µM using the conditions as described above for 5BPO. Both C4-and C5-substituted oxazoles formed corresponding 2-oxazolone as the only metabolite in the incubation mixture. T1/2 measuring disappearance of parent oxazoles are listed in Table 4 .
Maximum turnover of parent was observed in 5-(3-chlorophenyl)oxazole and 4-(2-bromophenyl)oxazole with T1/2 of 4 min. Relative amount of oxazolone metabolite was ≥98% with both oxazoles at 30 min of incubation. Lower turnover was seen with merimepodib, which had T1/2 of 201 min and 15% relative amount of oxazolone metabolite at 30 min of incubation, whereas the two 4, 5-di-substituted 2H-oxazoles were stable in mouse liver cytosol.
Discussion
In the present work we reported, for the first time, the oxidation of 2-oxazole to 2-oxazolone ( Fig. 7) catalyzed by aldehyde oxidase, as exemplified by conversion of 5-(3-bromophenyl)oxazole (5BPO) to its corresponding 2-oxazolone (M1) in mouse liver cytosol. Structure of M1 was characterized by LC-UV/MS/MS and confirmed by NMR.
The conversion of 2-oxazole to 2-oxazolone was found applicable to a number of other 4-or 5-substituted 2H oxazoles.
When incubated in mouse liver microsomes supplemented with NADPH, 5BPO gave rise to two oxidative metabolites, M1 (1%) and M2 (39%). Surprisingly, metabolite M1 (6%) was also present in the incubation devoid of NADPH (Fig. 1, panel A) ,
suggesting that the formation of M1 was likely due to the catalysis by residual cytosolic components present in the mouse liver microsomes. The initial finding prompted us to (Fig. 2) and accounted for 89% of 5BPO-related components based on the total UV peak areas.
Most oxazole ring metabolic transformations are mediated by cytochrome P450s, and often led to ring opened products (Dalvie et al., 2002) . In early 1950s, Bray and co- 2002). Ditazole, a 2-amino substituted oxazole, was reported to undergo sequential Ndealkylations to a 2-amino-oxazole, which was further hydrolyzed to 2-oxazolone via a proposed imine tautomer (Dalvie et al., 2002) . Similarly, 2-oxazolone has also been observed in the biotransformation of zoxazolamine, a 2-amino-5-chlorobenzoxazole (Van der Graaff et al., 1986) in the rat. However, its formation mechanism remained unclear. In the present study, 5BPO underwent oxazole C4 oxidation (M2) in liver microsomes, however, there was no evidence of oxazole ring opened metabolites.
Interestingly, 5BPO also underwent oxidation to 2-oxazolone, M1, in mouse liver have been reported in the literature (Hutzler, et al., 2012) for the AO mediated oxidation of BIBX1382 (33% incorporation), carbazeran (47.5%), and zaleplon (40%).
The second approach was to assess the effect of chemical inhibition on the reaction of 5BPO to M1. Raloxifene was reported to be the most potent inhibitor (Obach, 2004; Obach et al., 2004) of AO found thus far among other known inhibitors, such as cimetidine, isovanillin, methadone, etc Dastmalchi and Hamzeh-Mivehrod, 2005) . Obach further demonstrated that raloxifene could be an uncompetitive or a noncompetitive inhibitor depending on the substrate (Obach, 2004; Obach et al., 2004 ). In the chemical inhibitor studies, the formation of M1 from 5BPO
after incubation in the mouse liver cytosol in the presence of an inhibitor was compared with that of control incubation without an inhibitor (Table 2) . Under these conditions, two AO inhibitors, raloxifene and menadione, caused more than 90% inhibition of M1 formation, whereas three XO inhibitors, allopurinol, oxipurinol, and methotrexate exhibited minimal to weak (3-16%) inhibition. Consequently, results from the two approaches established the role of AO, but not XO, as the major enzyme responsible for metabolizing the 2H-oxazole in 5BPO to its corresponding 2-oxazolone (M1) ( Table   2) .
Notable difference is known among mammalian species in protein expression and catalytic activity of AO (Moriwaki et al., 1999; Beedham, 2001) . AO activity among species may vary depending on the substrate as well. However, in general AO catalytic activity seems to be high in monkeys, mice and humans and low in rats, whereas it is either minimal or absent in dogs (Beedham et al., 1987; Dalvie et al., 2010; Diamond et al., 2010; Pryde et al., 2010) . For example, a marked species difference was reported in metabolism of Zaleplon in human, monkey, and rat when administered orally. 5-Oxozaleplon resulting from oxidation of zaleplon by AO was observed as a major circulating metabolite in monkey and human than rat and was also a major liver S9 and cytosolic metabolite in monkey over rat (Kawashima et al., 1999) . Similarly, metabolite resulting from oxidation of Zoniporide by AO in the quinoline ring was a primary metabolite in humans and rats, but was not observed in dogs (Dalvie et al., 2010) . On the other hand, zebularine was found to be metabolized by AO with higher V max observed in mouse than human and monkey liver cytosols (Klecker et al., 2006) , and the order of AO activity, measured by the rate of vanillic acid formation from vanillin, was monkey > mouse > human > rat liver cytosol, with no activity seen in dog cytosol (Sahi et al., 2008) . When 5BPO was incubated in liver cytosols from various species including the rat, mouse, dog, monkey, and human, maximum turnover of 5BPO was observed in mouse liver cytosol (T1/2 = 7 min) followed by monkey liver cytosol (217 min). M1 was the only metabolite detected in these incubations. Relative percentage of M1, based on LC-UV area was 89% in mouse and 10% in monkey liver cytosol at 30 min of incubation.
Whereas, only trace amount of M1 was detected in rat and human liver cytosols. Dog liver cytosol, however, did not show any formation of M1. Similar results of M1 formation were obtained with liver cytosols acquired from different suppliers, BD Gentest and Xenotech, and with increased cytosolic protein concentration to 2 mg/mL (data not shown).
Despite our overall results were in agreement with species difference of AO catalytic activity reported in the literature (Kitamura et al., 2006; Sahi et al., 2008; Pryde et al., 2010) , more robust AO activity oxidizing 5BPO and related oxazoles was observed in mouse liver cytosol over monkey or human liver cytosol. This could possibly be an oxazole-chemotype specific or compound specific phenomenon.
Nevertheless, there are implications to drug discovery due to these findings because wild type or genetically engineered mouse models are frequently used in pharmacological studies of drug discovery, particularly in disease areas such as cancer and CNS. Thus, robust mouse AO-mediated metabolism and formation of significant metabolite may play a potential role in pharmacodynamics, toxicology, and pharmacokinetics in the mouse. Awareness of the reaction and necessary follow-up investigations using human matrices (cytosol and hepatocytes) in the preclinical setting will be certainly helpful to avoid surprise or buy down risk in the clinic.
Intrigued by the possibility that 2H-oxazole may represent a new substrate chemotype for AO mediated oxidation to 2-oxazolone, we further extended the investigation of this unique biotransformation to a number of 2H-oxazoles using mouse liver cytosol. As shown in Table 4 , among the compounds surveyed, C5-substituted Table 4 . Relative percentage of oxazolone metabolite was ≥98% in case of both 5-(3-chlorophenyl)oxazole and 4-(2-bromophenyl)oxazole and 15% in merimepodib at 30 min of incubation based on LC-UV area.
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The two 4, 5-di-substituted 2H-oxazoles did not yield any corresponding 2-oxazolone metabolite. Since the finding in Table 4 was obtained from only a limited set of 2H-oxazoles, it would be difficult to elaborate mechanistic aspect of substrate specificity. Suffice it to say that 2H-oxazoles, particularly, 4-or 5-substituted oxazoles, represent a new substrate chemotype for AO while each substrate requires careful experimental examination.
In summary, results from the present study revealed a novel ring oxidation of 2H oxazole to 2-oxazolone ( 
Figure 4
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